Implementation of AMNOG: An industry perspective.
In 2010, the Federal Parliament (Bundestag) of Germany passed a new law (Arzneimittelmarktneuordnungsgesetz, AMNOG) on the regulation of medicinal products that applies to all pharmaceutical products with active ingredients that are launched beginning January 1, 2011. The law describes the process to determine the price at which an approved new product will be reimbursed by the statutory health insurance system. The process consists of two phases. The first phase assesses the additional benefit of the new product versus an appropriate comparator (zweckmäßige Vergleichstherapie, zVT). The second phase involves price negotiation. Focusing on the first phase, this paper investigates requirements of benefit assessment of a new product under this law with special attention on the methods applied by the German authorities on issues such as the choice of the comparator, patient relevant endpoints, subgroup analyses, extent of benefit, determination of net benefit, primary and secondary endpoints, and uncertainty of the additional benefit. We propose alternative approaches to address the requirements in some cases and invite other researchers to help develop solutions in other cases.
Pfizer Deutschland GmbH, Linkstr. 10, 10785, Berlin, Germany.
Friedhelm
F
Leverkus
Chuang-Stein Consulting, 5857 Stoney Brook Road, Kalamazoo, MI, 49009, USA.
Christy
C
Chuang-Stein
D017326:Clinical Trials, Phase III as Topic / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D023381:Endpoint Determination; D033161:Government Regulation; D006801:Humans
AMNOG; Additional benefit; Comparator; Early benefit assessment; Endpoint; Net benefit; Subgroup